DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1304 Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant
human parathyroid hormone (1-84) on vertebral fracture and
bone mineral density in postmenopausal women with osteoporosis:
A randomized trial. Ann Intern Med, 2007, 146: 326–339.
Grey A, Lucas J, Horne A, et al. Vitamin D repletion in
patients with primary hyperparathyroidism and coexistent
vitamin D insufficiency. J Clin Endocrinol Metab, 2005,
90:2122–2126.
Grill V, Rankin W, Martin TJ. Parathyroid hormone related protein
(PTHrP) and hypercalcaemia. Eur J Cancer [A], 1998,
34:222–229.
Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone
resorption by alendronate and risedronate does not require
osteoclast apoptosis. Bone, 2001, 29:553–559.
Hay DL, Christopoulos G, Christopoulos A, et al. Pharmacological
discrimination of calcitonin receptor: receptor activitymodifying
protein complexes. Mol Pharmacol, 2005, 67:
1655–1665.
Herberth J, Monier-Faugere MC, Mawad HW, et al. The five most
commonly used intact parathyroid hormone assays are useful
for screening but not for diagnosing bone turnover abnormalities
in CKD-5 patients. Clin Nephrol, 2009, 72: 5–14.
Hewison M, Zehnder D, Chakraverty R, et al. Vitamin D and
barrier function: A novel role for extra-renal 1α-hydroxylase.
Mol Cell Endocrinol, 2004, 215:31–38.
Hirsch PF, Baruch H. Is calcitonin an important physiological
substance? Endocrine, 2003, 21:201–208.
Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone
and teriparatide for the treatment of osteoporosis: A
review of the evidence and suggested guidelines for its use.
Endocrine Rev, 2005, 26:688–703.
Hollis BW, Wagner CL. Assessment of dietary vitamin D
requirements during pregnancy and lactation. Am J Clin Nutr,
2004, 79:717–726.
Institute of Medicine (U.S.). Dietary Reference Intakes:
Applications in Dietary Planning. National Academy Press,
Washington, 2003, pp 969–998.
Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin
D supplementation and the risk of fractures. N Engl J Med,
2006, 354:669–683.
Johnston CC Jr, Miller JZ, Slemenda CW, et al. Calcium supplementation
and increases in bone mineral density in children.
N Engl J Med, 1992, 327:82–87.
Jolette J, Wilker CE, Smith SY, et al. Defining a noncarcinogenic
dose of recombinant human parathyroid hormone 1-84 in a 2-
year study in Fischer 344 rats. Toxicol Pathol, 2006, 34: 929–940.
Jüppner H, Potts JT Jr. Immunoassays for the detection of
parathyroid hormone. J Bone Miner Res, 2002, 17 suppl
2:N81–N86.
Jüppner HW, Gardella TJ, Brown EM, et al. Parathyroid hormone
and parathyroid hormone-related peptide in the regulation
of calcium homeostasis and bone development. In:
Endocrinology. (DeGroot LJ, Jameson JL, eds.), W.B.
Saunders Company, Philadelphia, 2001, pp. 969–998.
Khosla S. Minireview: The OPG/RANKL/RANK system.
Endocrinology, 2001, 142:5050–5055.
Kissmeyer AM, Binderup L. Calcipotriol (MC 903):
Pharmacokinetics in rats and biological activities of metabolites.
A comparative study with 1,25(OH) 2
D 3
. Biochem Pharmacol,
1991, 41:1601–1606.
SECTION V
HORMONES AND HORMONE ANTAGONISTS
Kowalzick L. Clinical experience with topical calcitriol (1,25-
dihydroxyvitamin D 3
) in psoriasis. Br J Dermatol, 2001, 144
Suppl 58:21–25.
Kragballe K, Iversen L. Calcipotriol. A new topical antipsoriatic.
Dermatol Clin, 1993, 11:137–141.
Levine MA, Germain-Lee E, Jan de Beur S. Genetic basis for
resistance to parathyroid hormone. Horm Res, 2003, 60 suppl
3:87–95.
Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate
on bone mineral density and the incidence of fractures in postmenopausal
osteoporosis. The Alendronate Phase III
Osteoporosis Treatment Study Group. N Engl J Med, 1995,
333:1437–1443.
Lin HY, Harris TL, Flannery MS, et al. Expression cloning of an
adenylate cyclase-coupled calcitonin receptor. Science, 1991,
254:1022–1024.
Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior
to pamidronate in the treatment of hypercalcemia of malignancy:
A pooled analysis of two randomized, controlled clinical
trials. J Clin Oncol, 2001, 19:558–567.
Malloy PJ, Pike JW, Feldman D. Hereditary 1,25-dihydroxyvitamin
D-resistant rickets. In: Vitamin D (Feldman D, Pike
JW, Glorieux FH, eds.), Elsevier, Burlington, MA, 2005,
pp. 1207–1237.
Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone.
Recent Prog Horm Res, 2002, 57:385–409.
Martin KJ, Gonzalez EA, Gellens M, et al. 19-Nor-1-α-25-dihydroxyvitamin
D 2
(Paricalcitol) safely and effectively reduces
the levels of intact parathyroid hormone in patients on
hemodialysis. J Am Soc Nephrol, 1998, 9:1427–1432.
Martin TJ, Ng KW. Mechanisms by which cells of the osteoblast
lineage control osteoclast formation and activity. J Cell
Biochem, 1994, 56:357–366.
McDonnell DP, Mangelsdorf DJ, Pike JW, et al. Molecular
cloning of complementary DNA encoding the avian receptor
for vitamin D. Science, 1987, 235:1214–1217.
Michaelsson K, Melhus H, Bellocco R, et al. Dietary calcium
and vitamin D intake in relation to osteoporotic fracture risk.
Bone, 2003, 32:694–703.
Monier-Faugere MC, Geng Z, Mawad H, et al. Improved assessment
of bone turnover by the PTH-(1-84)/large C-PTH fragments
ratio in ESRD patients. Kidney Int, 2001, 60:1460–1468.
Morony S, Warmington K, Adamu S, et al. The inhibition of
RANKL causes greater suppression of bone resorption and
hypercalcemia compared with bisphosphonates in two models
of humoral hypercalcemia of malignancy. Endocrinology,
2005, 146:3235–3243.
Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin
D receptor ligands. Endocrine Rev, 2005, 26:662–687.
Naro F, Perez M, Migliaccio S, et al. Phospholipase D- and PKC
isoenzyme-dependent signal transduction pathways activated
by the calcitonin receptor. Endocrinology, 1998, 139:
3241–3248.
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid
hormone (1-34) on fractures and bone mineral density in postmenopausal
women with osteoporosis. N Engl J Med, 2001,
344:1434–1441.
O’Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and
remodeling by PTH receptor signaling in osteocytes. PLoS
ONE, 2008, 3:e2942.